

### SECTION-1: Identification of the substance / mixture and the company / undertaking

<b>Catalogue Number</b>	CS-T-51137
<b>Product Name</b>	Cinerin I
<b>CAS No.</b>	25402-06-6
<b>Category</b>	API
<b>Synonyms</b>	Not available
<b>Brand</b>	Clearsynth Labs Ltd.
<b>Identified uses</b>	Laboratory Chemicals
<b>Uses advised against</b>	Not available
<b>Company</b>	Clearsynth Labs Ltd. Mumbai, India
<b>Emergency Phone #</b>	+91-22-245045900
<b>REACH No.</b>	Not available

### SECTION 2: Hazards identification

**Disclaimer:** This is sample MSDS. Please email [sales@clearsynth.com](mailto:sales@clearsynth.com) for more details.

#### 2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Acute toxicity (Category 4)

#### 2.2 Label Elements

**Signal Word:** Warning



#### Hazard Statement(s)

Code	Statement
H302	Harmful if swallowed.
H400	Not available
H410	Not available

#### Precautionary Statement(s)

Code	Statement
P264	Wash hands thoroughly after handling.
P270	Not available
P273	Not available
P301+P317	Not available
P330	Not available
P391	Not available
P501	Dispose of contents/container in accordance with local/regional/national/international regulation

### SECTION 3: Composition / information on ingredients

#### 3.1 Substance

Component : Cinerin I

CAS Number : 25402-06-6

Molecular Formula : Not available

Molecular Weight : Not available

Parent Chemical : Not available

Synonyms : Not available

Concentration : Not available

### SECTION 4: First aid measures

#### SECTION 4: First-aid measures

##### 4.1 Description of first aid measures

- General advice: Remove from exposure. Show this SDS to medical personnel.
- Inhalation: Move person to fresh air. If symptoms persist, get medical attention.
- Skin contact: Wash with plenty of soap and water. Remove contaminated clothing and wash before reuse. Get medical attention if irritation persists.
- Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Get medical attention if irritation persists.
- Ingestion: Rinse mouth. Do not induce vomiting unless directed by medical personnel. Get medical attention.

##### 4.2 Most important symptoms and effects, both acute and delayed

- Not available.

##### 4.3 Indication of any immediate medical attention and special treatment needed

- Treat symptomatically.
- No data available.

### SECTION 5: Firefighting measures

### SECTION 5: Fire-fighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media: Use extinguishing measures appropriate to surrounding fire (e.g., water spray, alcohol-resistant foam, dry chemical, carbon dioxide).
- Unsuitable extinguishing media: Not available.

#### 5.2 Special hazards arising from the substance or mixture

- Specific hazards: Not available.
- Hazardous combustion products: Not available.

#### 5.3 Advice for firefighters

- Wear self-contained breathing apparatus (SCBA) and full protective gear.
- Cool containers with water spray if exposed to fire.
- Avoid inhalation of combustion products.

### SECTION 6: Accidental release measures

#### SECTION 6: Accidental release measures

##### 6.1 Personal precautions, protective equipment and emergency procedures

- Avoid breathing dust/vapors/mist.
- Avoid contact with skin and eyes.
- Use appropriate personal protective equipment (see Section 8).
- Ensure adequate ventilation.

##### 6.2 Environmental precautions

- Prevent further leakage or spillage if safe to do so.
- Avoid release to the environment. Do not allow to enter drains/surface waters/groundwater.

##### 6.3 Methods and material for containment and cleaning up

- Contain spill.
- Collect spilled material using non-sparking tools and place in a suitable, labeled container for disposal.
- Clean spill area with suitable absorbent material.

##### 6.4 Reference to other sections

- See Section 8 for personal protective equipment.
- See Section 13 for disposal considerations.

### SECTION-7: Handling and storage

#### SECTION 7: Handling and storage

##### 7.1 Precautions for safe handling

- Handle in accordance with good industrial hygiene and safety practice.
- Avoid formation of dust.
- Avoid contact with skin, eyes, and clothing.
- Avoid breathing dust/vapors/mist.
- Use only with adequate ventilation.

##### 7.2 Conditions for safe storage, including any incompatibilities

- Store in a tightly closed container.

- Store in a cool, dry, well-ventilated place.
- Protect from moisture.
- Incompatible materials: Not available.

### 7.3 Specific end use(s)

- API / laboratory and research use. Not for food, drug, or household use unless specifically indicated by supplier.
- No data available.

## SECTION 8: Exposure controls / personal protection

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

- Occupational exposure limits: Not available.
- Biological limit values: Not available.

#### 8.2 Exposure controls

- Engineering controls: Provide adequate ventilation. Use local exhaust where dust or aerosols may be generated.
- Personal protective equipment (PPE):
  - Eye/face protection: Safety glasses with side shields or chemical splash goggles.
  - Skin protection: Protective gloves. Wear protective clothing as appropriate.
  - Respiratory protection: If ventilation is inadequate or dust/aerosols are generated, use an appropriate respirator in accordance with applicable regulations.
- Hygiene measures: Wash hands after handling. Do not eat, drink, or smoke when using this product.

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available

Property	Value
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

## SECTION 10: Stability and reactivity

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity

- No data available.

#### 10.2 Chemical stability

- Stable under recommended storage conditions.

#### 10.3 Possibility of hazardous reactions

- No data available.

#### 10.4 Conditions to avoid

- Avoid heat, sparks, open flames, and other ignition sources.
- Avoid dust generation.
- Avoid moisture (if applicable).

#### 10.5 Incompatible materials

- Not available.

#### 10.6 Hazardous decomposition products

- Not available.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

- Acute toxicity: The clinical manifestations of inhalation exposure to pyrethrins can be local or systemic. Localized reactions confined to the upper respiratory tract include rhinitis, sneezing, scratchy throat, oral mucosal edema, and

even laryngeal mucosal edema. Localized reactions of the lower respiratory tract include cough, shortness of breath, wheezing, and chest pain. An asthmalike reaction occurs with acute exposures in sensitized patients.

Hypersensitivity pneumonitis characterized by chest pain, cough, dyspnea, and bronchospasm may occur in an individual chronically exposed. Large amounts may cause nausea, vomiting, tinnitus, headache, and other central nervous system disturbances. (A566) LD50: 2370 mg/kg (Oral, Rat) (T58) LD50: 1030 mg/kg (Oral, Rat) (T58)

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: /HUMAN EXPOSURE STUDIES/ When 200 people (177 women & 23 men) were patch tested with a 1% water dispersion of pyrethrins, no evidence of primary irritancy or of sensitization was found. /Pyrethrins/ /LABORATORY ANIMALS: Acute Exposure/ In a study of dermal sensitization in guinea-pigs with a modified Buehler protocol, /pyrethrum extract/ were not sensitizing.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: The clinical manifestations of inhalation exposure to pyrethrins can be local or systemic. Localized reactions confined to the upper respiratory tract include rhinitis, sneezing, scratchy throat, oral mucosal edema, and even laryngeal mucosal edema. Localized reactions of the lower respiratory tract include cough, shortness of breath, wheezing, and chest pain. An asthmalike reaction occurs with acute exposures in sensitized patients. Hypersensitivity pneumonitis characterized by chest pain, cough, dyspnea, and bronchospasm may occur in an individual chronically exposed. Large amounts may cause nausea, vomiting, tinnitus, headache, and other central nervous system disturbances. (A566)
- Aspiration hazard: No data available.

#### Likely routes of exposure

- The clinical manifestations of inhalation exposure to pyrethrins can be local or systemic. Localized reactions confined to the upper respiratory tract include rhinitis, sneezing, scratchy throat, oral mucosal edema, and even laryngeal mucosal edema. Localized reactions of the lower respiratory tract include cough, shortness of breath, wheezing, and chest pain. An asthmalike reaction occurs with acute exposures in sensitized patients. Hypersensitivity pneumonitis characterized by chest pain, cough, dyspnea, and bronchospasm may occur in an individual chronically exposed. Large amounts may cause nausea, vomiting, tinnitus, headache, and other central nervous system disturbances. (A566)

#### Symptoms related to the physical, chemical and toxicological characteristics

- Pyrethrins exert their effect by prolonging the open phase of the sodium channel gates when a nerve cell is excited. They appear to bind to the membrane lipid phase in the immediate vicinity of the sodium channel, thus modifying the channel kinetics. This blocks the closing of the sodium gates in the nerves, and thus prolongs the return of the membrane potential to its resting state. The repetitive (sensory, motor) neuronal discharge and a prolonged negative afterpotential produces effects quite similar to those produced by DDT, leading to hyperactivity of the nervous system which can result in paralysis and/or death. (L857, A560)

## SECTION 12: Ecological information

### SECTION 12: Ecological information

#### 12.1 Toxicity

- No data available.

### 12.2 Persistence and degradability

- No data available.

### 12.3 Bioaccumulative potential

- No data available.

### 12.4 Mobility in soil

- No data available.

### 12.5 Results of PBT and vPvB assessment

- Not available.

### 12.6 Endocrine disrupting properties

- No data available.

### 12.7 Other adverse effects

- No data available.

## SECTION 13: Disposal considerations

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

- Dispose of contents/container in accordance with local/regional/national/international regulations.
- Do not discharge to drains.
- Incineration or disposal via a licensed waste contractor may be appropriate.
- Waste classification: Not available.

## SECTION 14: Transport information

### SECTION 14: Transport information

- UN number: Not available.
- UN proper shipping name: Not available.
- Transport hazard class(es): Not available.
- Packing group: Not available.
- Environmental hazards: Not available.
- Special precautions for user: Not available.
- Transport in bulk according to IMO instruments: Not available.

Note: Transport classification may vary by mode (ADR/RID, IMDG, IATA). Confirm with shipping documentation and applicable regulations.

## SECTION 15: Regulatory information

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- Regulatory status (inventories/notifications): Not available.
- GHS classification: Not available.
- Label elements: Not available.

### 15.2 Chemical safety assessment

- No data available.

## SECTION 16: Other information

### SECTION 16: Other information

- Product name: Cinerin I
- Catalog No.: CS-T-51137
- CAS No.: 25402-06-6
- Supplier: Clearsynth Labs Ltd., Mumbai, India
- Emergency phone: +91-22-245045900

#### Disclaimer

- The information provided is believed to be accurate based on available data, but no warranty is expressed or implied. Users must determine suitability for their particular purpose and comply with all applicable laws and regulations.

#### Revision information

- Revision date: Not available.
- Version: Not available.

## DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.